DRAW-TO-THAW
LIVE

Serial Number

98309999

Owner

New York Blood Center, Inc.

Attorney

CYNTHIA JOHNSON WALDEN

Filing Date

Dec 12, 2023

Add to watchlist:

No watchlists yet
View on USPTO

DRAW-TO-THAW Trademark

Serial Number: 98309999

DRAW-TO-THAW is a trademark filed by New York Blood Center, Inc. on December 12, 2023. The trademark is classified under Class 5 (Pharmaceuticals), Class 39 (Transportation & Storage), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 35 (Advertising & Business). The application is currently pending registration.

Owner Contact Info

New York Blood Center, Inc.

310 East 67th Street
New York, NY 10021

Entity Type: 99

Trademark Details

Filing Date

December 12, 2023

Registration Date

Not Registered

Published for Opposition

November 5, 2024

Goods & Services

Providing independent review of clinical trials for business purposes

Storage of blood and stem cells for medical use; human stem cell storage for medical use

Cryopreservation of human cells

Blood bank services; tissue bank services; collection and preservation of human blood, red blood cells, plasma and bone marrow; apheresis, namely, removal, treatment, and processing of human blood; T cell isolation services, namely, medical services involving the removal, treatment, and processing of human blood to isolate t cells

Pharmaceutical research services and conducting pharmaceutical clinical trials for others; medical research laboratory services, namely, cell processing services for use by others

Products to support and manage transfusion medicine and regenerative medicine from discovery through development and to the clinic, namely, blood plasma, blood for medical purposes, blood products, namely cord blood, leukopaks, buffy coats for medical use, antibody positive blood plasma, blood components for medical purposes, namely, phenotyped red cell units and monoclonal antibodies, cord blood all for use in medical diagnoses and treatment; mononuclear cells for medical use, progenitor cells for medical use, antibody preparations for medical use in medical clinical trials and medical purposes

Filing History

TEAS STATEMENT OF USE RECEIVED
Jun 16, 2026 EISU
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec 13, 2025 EXRA
SOU EXTENSION 2 GRANTED
Dec 12, 2025 EX2G
SOU EXTENSION 2 FILED
Dec 12, 2025 EXT2
SOU TEAS EXTENSION RECEIVED
Dec 12, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jun 18, 2025 EXRA
SOU EXTENSION 1 GRANTED
Jun 17, 2025 EX1G
SOU EXTENSION 1 FILED
Jun 17, 2025 EXT1
SOU TEAS EXTENSION RECEIVED
Jun 17, 2025 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Dec 17, 2024 NOAM
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Dec 6, 2024 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Dec 6, 2024 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Dec 6, 2024 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Dec 6, 2024 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Dec 6, 2024 COAR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Nov 5, 2024 NPUB
PUBLISHED FOR OPPOSITION
Nov 5, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Oct 16, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 12, 2024 CNSA
EXAMINER'S AMENDMENT ENTERED
Sep 12, 2024 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Sep 12, 2024 GNEN
EXAMINERS AMENDMENT E-MAILED
Sep 12, 2024 GNEA
EXAMINERS AMENDMENT -WRITTEN
Sep 12, 2024 CNEA
PREVIOUS ALLOWANCE COUNT WITHDRAWN
Sep 12, 2024 ZZZX
WITHDRAWN FROM PUB - OG REVIEW QUERY
Aug 6, 2024 PBCR
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 19, 2024 CNSA
EXAMINER'S AMENDMENT ENTERED
Jul 19, 2024 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jul 19, 2024 GNEN
EXAMINERS AMENDMENT E-MAILED
Jul 19, 2024 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jul 19, 2024 CNEA
ASSIGNED TO EXAMINER
Jul 11, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 14, 2024 NWOS
NEW APPLICATION ENTERED
Dec 12, 2023 NWAP